NKMax NYSE

South Korean chipmaker Magnachip Semiconductor Corp. plans to sell its display business by the end of the first half as part of a strategic shift to...

Viva Republica Inc., a leading South Korean fintech unicorn and operator of mobile financial super app Toss, has dropped its plan to go public in th...

South Korea’s LG Group and Seoul-based Qraft Technologies Inc. have jointly launched an exchange-traded fund (ETF) that selects holdings relat...

NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...

South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...

South Korean natural killer cell drug maker NKMax Co. announced in a regulatory filing on Friday that it has signed a supply contract with China's S...

The listing in the US of NKGen Biotech, the American subsidiary of South Korean developer of natural killer (NK) cell therapy NKMax Co., is coming i...

NKGen Biotech, the US affiliate of South Korea's natural killer (NK) cell therapy developer NK Max, on Friday said it signed a letter of intent (LOI) ...

NKMax Co., a South Korean cancer drug maker, is in talks with local and foreign investors in a bid to list its California-based unit NKGen Biotech I...

SK Inc., the investment-focused holding company of South Korea’s SK Group, is set to pocket a sixfold return from its investment in SES Holdin...

South Korean millennials in their 20s and 30s are rushing to Nasdaq and the New York Stock Exchange (NYSE) amid skyrocketing real estate prices in t...

Coupang Corp., 37% owned by SoftBank Group, is set to become the first Korean company to list directly on the New York Stock Exchange, with its valu...